1. Allergan Aesthetics to present AA Signature™ approach at AMWC Dubai event. 2. Successful launch in 25 countries boosts ABBV's aesthetics portfolio. 3. Experts to discuss new trends in medical aesthetics at the symposium. 4. 94% of consumers desire improved facial skin quality according to survey. 5. AA Signature™ focuses on personalized, multimodal treatment for patients.
The successful launch of the AA Signature™ approach indicates strong market demand, historically leading to revenue increases for ABBV. The emphasis on new aesthetic trends can spur further growth.
The article's focus on a new multimodal aesthetic treatment approach strengthens ABBV’s competitive position and potential profitability, making it highly relevant to ABBV's stock performance.
The market's shift towards personalized aesthetics is likely to foster sustained growth over time, similar to previous expansions in skincare and aesthetics market segments.
IRVINE, Calif., Sept. 25, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience, at the upcoming Internationally recognized Aesthetic Anti-Aging Medicine World Congress (AMWC), taking place in Dubai from Wednesday 1 – Friday 3 October 2025.
The AA Signature™ treatment approach harnesses Allergan Aesthetics' leading product portfolio and is supported by advanced education and business resources for healthcare professionals. Designed to meet evolving patient needs and enhance clinical practice, AA Signature™ has been successfully launched in over 25 countries* this year and is planned for further expansion. The protocol-driven methodology currently addresses different globally recognized patient needs including Lift Up, Distinct Definition, and improved skin quality.
"Aesthetic trends worldwide are shifting toward a more natural, individualized look. The AA Signature™ treatment approach is designed to meet these emerging patient needs, offering a holistic method that recognizes and aligns with each patient's unique goals. The approach leverages Allergan Aesthetics' advanced and versatile portfolio to empower healthcare professionals to deliver multimodal treatment plans for tailored results, strengthening patient relationships and encouraging long-term retention," said Mark Wilson, SVP, International Allergan Aesthetics. We've received excellent feedback from healthcare practitioners since launching AA Signature™, and we look forward to continuing to showcase real-world results and data in the coming months."
AMWC Dubai 2025 AMI Symposium
The Allergan Medical Institute hosted symposium 'Design your patients' look with the NEW Signature approach by Allergan Aesthetics and a decade of MD Codes™ excellence' will take place at 11AM-1PM on Wednesday, 1 October in Baniyas Ballroom 1, Grand Hyatt Dubai.
World-renowned experts including plastic surgeon and creator of the MD Codes™ system Dr Mauricio de Maio will explore the paradigm shift in medical aesthetics and decode the new AA Signature™ approach.
A live injection of AA Signature™ Lift Up will be performed, focusing on how the multimodal approach can help address patient needs including added lift, structure and skin firmness as research finds patients long for a lifted and more defined appearance1,2†.
Allergan Aesthetics Global Medical Affairs Symposium on Skin Quality Multimodal Mastery
A single-strategy treatment plan may not be enough to unlock the skin's full potential7, and a multimodal approach is the focus of this year's medical symposium, 'Mastering Skin Quality - Integrating Aesthetic Modalities for Holistic Skin Quality Improvement' on Wednesday, 1 October at 2PM-4PM in Al Ameera Ballroom 2, Grand Hyatt Dubai.
With 94% of people wanting to improve their facial skin quality3‡, Allergan Aesthetics brings together globally renowned leaders in aesthetics Dr. Rami Abadi, Dr. Sylwia Godlewska, Dr. Maurizio Cavallini and Dr. Mansi Mukherjee to offer a deep dive into understanding patient needs related to skin quality and exploring the integration of a holistic, multi-modal aesthetic approach—including hyaluronic acid (HA), biostimulators, and hybrid injectables—within clinical practice to enhance skin quality and elevate patient satisfaction.
Meet The Experts
Allergan Aesthetics will host a series of Meet the Experts sessions live from booth B100 across the three day event, featuring:
Allergan Aesthetics Booth – B100
Attendees can discover more about the AA Signature approach and explore the Allergan Aesthetics facial aesthetics portfolio with immersive product experiences at networking opportunities at the booth.
New clinical data
Additionally, a personalized aesthetics approach and skin quality are topics that feature amongst 7 e-posters that have been accepted across various products, treatments and indications, furthering Allergan Aesthetics' commitment. Titles and authors include:
Presentation Topic | Poster Title | Authors |
MaxDiff Characteristics Likely to Treat - Middle Eastern Women ABS | Facial and Body Aesthetic Concerns and Treatment Interests Among Middle Eastern Women: Results From Middle Eastern Female-Identifying Respondents of a Large US Survey of Aesthetically Inclined Adults | Raafat Lakis, Mona Sadeghpour, Omer Ibrahim, Amir Moradi, Mohammad Saleh Al-Khowailed, Ammar Raza, Nazanin Ashourian, Elena Dimitrijevic, Sara Sangha |
Personalized Ax - Lift | Personalized Aesthetic Treatment for Nonsurgical Lift Effect Using Multimodal Portfolio of Injectables | Juliana Chieppe; Jake Sloane; Peter Peng; Emily Schultz; Wang Ye; Ahmed Yasin |
Personalized Ax - Skin | Personalized Aesthetic Treatment to Improve Common Skin Quality Needs Using a Multimodal Portfolio of Injectables | Jake Sloane; Juliana Chieppe; Yuexing Song; Peter Peng; Emily Schultz; Ahmed Yasin |
Juvéderm® VYCROSS™, BOTOX® upper and midface treatment and PROs | Infraorbital and Periorbital Rejuvenation with Sequential Use of Hyaluronic Acid Fillers and OnabotulinumtoxinA | Gregory Goodman; Frank Lin; Samira Baharlou; Sarah Boxley; Pierre Cuvelier; Cara McDonald; Joan Vandeputte; Ivar Van Heijningen; Julia K. Garcia; Traci Baker; Smita Chawla; Carola de la Guardia |
Juvéderm® VOLUMA temple China study | Improvement in Temple Hollowing With VYC-20L Filler: A Multicenter, Randomized Controlled Trial of Safety and Effectiveness in a Chinese Population | Yun Xie, Qingfeng Li, Jiaming Sun, Lei Wang, Qian Tan, Chengyuan Wang, Dong Li, Hongyi Zhao, Chenliang Deng, Jingli Shi, Smita Chawla |
Juvéderm® VOLUMA temple repeat treatment and PROs from US study | Efficacy and Safety of VYC-20L Hyaluronic Acid Filler in Temple Hollowing: Initial Treatment and Maintenance Results from a Multicenter Study | José R. Montes, Derek Jones, Brian Biesman, Kenneth Beer, Deirdre Hooper, Steve Yoelin, Leslie Baumann, Kelly Leung, Shirley Chung, Smita Chawla |
HArmonyCa™ Int'l Interim | An International, Multicenter, Evaluator-blinded, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation | A Nikolis, N Demosthenous, S Humphrey, F Urdiales, M Salomon, A Schumacher |
Notes to Editors
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit. www.allerganaesthetics.com.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Global Media: | Investors: |
Michael Salzillo | Liz Shea |
U.S. Media: | |
Adelle Infante | |
Disclaimers
Material developed and funded by Allergan Aesthetics, an AbbVie company.
Copyright 2023 AbbVie. All rights reserved. All trademarks are the property of their respective owners.
Footnotes:
*AA Signature has rolled out in the following 25 countries so far this year: Spain / Iberia, Turkey, Brazil, Australia, Taiwan, France, Mexico, Columbia, Argentina, Chile, Italy, Bulgaria, Sweden, Finland, Denmark, Norway, China, GULF, South Africa, and other Central and Eastern Europe countries.
†Qualitative data from an online community platform captured over 5 days with a range of consumer types (naïve considerers, engaged considerers, users) from a range of ages (20–34, 34–49 and 50+) from Canada, Brazil, China.
‡94% of 14,584 people interviewed in a global survey. People desired to improve their facial skin, and terms such as radiance and healthy, glowing skin were requested by patients seeking improvements in their appearance. The term 'skin quality' encompasses this collection of desired outcomes.
References:
View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-to-showcase-multimodal-treatment-approach-and-continued-commitment-to-skin-quality-at-amwc-dubai-302565990.html
SOURCE AbbVie